Purpose: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases.
T hree retinal diseases (neovascular age-related macular degeneration [nAMD] , diabetic macular edema [DME] , and retinal vein occlusion [RVO] ) are associated with a major health care burden in Western countries, mainly because of their chronic nature and poor visual outcomes if left untreated. Although the underlying etiology of these diseases is complex, there is now evidence to show that vascular endothelial growth factor (VEGF) plays a key role in their pathogenesis. [1] [2] [3] This provides a common rationale for targeting VEGF in retinal diseases. Anti-VEGF agents are effective options, but monthly injections and monthly clinic visits may reduce long-term compliance and increase costs. Monthly approaches have their origins in the standard design of pivotal randomized studies.
To optimize the benefit:risk ratio and costeffectiveness of anti-VEGF agents, a number of flexible dosing strategies are increasingly being used in clinical practice. These include a variety of as-needed (pro re nata [PRN] ) approaches (i.e., regular follow-up with treatment that is determined mostly by recurrent macular fluid on optical coherence tomography [OCT]) [4] [5] [6] and treat-and-extend regimens (TERs), which may involve fixed treatment intervals until clinical remission, usually determined by OCT, followed by increasing treatment intervals. A retrospective, observational study of intravitreal ranibizumab in nAMD that examined differences between management in 2007 and 2010 (in 125 eyes) showed that the visual gain was greater (+6.0 vs. +0.7 Early Treatment Diabetic Retinopathy Study letters; P = 0.0003) and eyes also received more injections (5.0 vs. 3.8; P , 0.0001) in 2010 than in 2007. The temporal change may be because of a number of factors, including the use of alternative strategies, such as TER. 7 However, this study did not directly assess the impact of TER or alternative strategies, and large-scale comparisons in different populations are lacking. There is also wide variation in dosing regimen selection (including TER) in clinical practice 8 and across disease areas. 9 Evaluating the evidence and developing a consensus on the most effective TER protocol would potentially improve regimen selection in clinical practice and enable physicians to understand the rationale for TER, resulting in more considered dosing choices. TER was also regarded as a flexible dosing strategy to reduce retreatment burden in the recently updated EURETINA guidelines. 10 There is also evidence to suggest that intraindividual retreatment intervals are stable but interindividual recurrence intervals are variable. 11, 12 This is an ideal basis for individualized treatment plans with TER.
Objectives and Methods
The aim of this report is to provide a review and consensus on the best practice approach to the use of TER with anti-VEGF agents (intravitreal ranibizumab, intravitreal bevacizumab, or intravitreal aflibercept) in retinal diseases based on currently available evidence. The review was developed following a roundtable discussion by international retina specialists (consensus panel), which was held in Rome, Italy (26 January 2014) , and was also reviewed at a second roundtable meeting held in Tokyo, Japan (01 April, 2014). During the initial meeting, scientific evidence and clinical cases were discussed, followed by the development of an algorithm on the recommended approach to TER; it is envisaged that this algorithm will be useful to ophthalmologists and health care providers with an interest in the long-term management of patients with retinal disease. The scientific evidence has been graded using European guidance (see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IAE/A346). 13 Scientific Evidence TER studies. There are 11 published TER studies in more than 1,000 patients with nAMD ( APTC-ATE, Antiplatelet Trialists' Collaboration-defined arterial thromboembolic event; BCVA, best-corrected visual acuity; BL, baseline; CFT, central foveal thickness; CMT, central macular thickness; CNV, choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; FU, follow-up; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; LogMAR, logarithm of the minimum angle of resolution; MI, myocardial infarction; nAMD, neovascular age-related macular degeneration; NV, neovascularization; RAP, retinal angiomatous proliferation; SRF, subretinal fluid; TER, treat-and-extend; VA, visual acuity. and 3 comparator studies against PRN approaches (Table 2) . [25] [26] [27] The studies showed an improvement in both visual and anatomical outcomes (central foveal thickness/central retinal thickness/choroidal NV size) using TER, and this approach was associated with greater (and possibly earlier) visual improvements compared with PRN over a period ranging from 6 months to 36 months, with mean injections around 8 in the first year and around 6 to 7 in the second year. There were no major safety concerns with the TER approach, and no eyes developed submacular hemorrhage during an extended follow-up period. The TER approach was similar across studies, with most using a 3-monthly loading scheme until no fluid was seen on OCT followed by 2-week extension intervals up to a maximum of 10 weeks to 12 weeks unless fluid or hemorrhage recurred.
The criteria for treatment extension in each study are summarized in Table 3 . [14] [15] [16] [17] [18] [19] [20] [21] 23, 24 In the majority of studies, a dry macula was required before extension (i.e., no fluid on OCT and no persistent or new hemorrhage). Resolution of pigment epithelial detachment was not required before extension; this was particularly relevant in eyes with Type 1 (subretinal pigment epithelium) neovascularization (NV) that will often continue to manifest pigment epithelial detachment after a loading scheme. A number of studies also required a stable disease state before extension and used no change or increase in vision loss or central retinal thickness as markers for treatment change. Fluid recurrence was usually used as a marker for interval shortening. It is expected that fluid recurrence will occur at some stage during an extension phase (making it an important marker); it can, therefore, be used to refine the optimal dosing interval during the follow-up period. At present, there is no optimal approach or guidance for switching from PRN to TER. Changing dosing regimen may be guided by the criteria for extension that have already been described.
There are few studies using TER in macular edema (ME) secondary to RVO or DME (Table 4) . [28] [29] [30] The consensus panel found the evidence for TER in ME/RVO and DME too scarce to provide general guidance at present. However, based on clinical experience, the proposed TER algorithm will be applicable to ME/RVO and DME. The TER attempts to individualize the dosing regimen and reduce treatment burden (both visits and injections) compared with fixed monthly dosing or monthly visits with OCT-guided regimens, and it can lead to fewer visits (albeit more injections, particularly in the first year of therapy) compared with PRN dosing. These are also considerations for ME/RVO and DME patients. It is also hoped that some of the ongoing TER studies (Table 5) will add further clarity. This will also be valuable in improving the evidence-based treatment guidelines as most of the studies (Tables 1, 2 , and 4) are low grade (Level 3-4 evidence) and not registration studies.
Extended follow-up (non-TER) studies. The majority of studies using a TER approach to treatment were performed using intravitreal ranibizumab or bevacizumab. The evidence for intravitreal aflibercept is largely supported by studies that used a 3-to 5-monthly 2 mg dosing scheme followed by dosing every 8 weeks (2q8). Although these were not TER schedules, they are useful in that they illustrate outcomes using an extended dosing regimen in a randomized setting and are registration studies (Level 1 evidence).
In 2 multicenter, active-controlled, randomized studies (VIEW 1 and VIEW 2), 2,419 patients with nAMD and subfoveal choroidal neovascularization were randomized to intravitreal aflibercept 0.5 mg or 2.0 mg monthly or 2 mg every 2 months after 3 monthly loading doses (2q8) or intravitreal ranibizumab 0.5 mg monthly. 31 All intravitreal aflibercept groups were noninferior to monthly intravitreal ranibizumab for vision maintenance at Week 52 (i.e., loss of ,15 Early Treatment Diabetic Retinopathy Study letters). Intravitreal aflibercept (any regimen) and monthly intravitreal ranibizumab were equally effective in improving bestcorrected visual acuity over a 96-week follow-up, but the intravitreal aflibercept 2q8 group was associated with an average of 5 fewer injections. 32 In addition to it being given at a higher dose, it is possible that the longer dosing regimen with intravitreal aflibercept 2.0 mg compared with intravitreal ranibizumab 0.5 mg observed in the VIEW studies may be linked to differences in binding affinity and a longer intravitreal half-life (approximately 9.0 days vs. 7.1 days, respectively). 33 In the 18-month follow-up of the GALILEO study, visual and anatomical improvements observed with monthly intravitreal aflibercept dosing in patients with ME secondary to central RVO were maintained when the treatment intervals were extended. 34 Intravitreal aflibercept 2q8 has also been shown to be effective in DME patients in two similarly designed, activecontrolled, randomized studies (VIVID-DME and VISTA-DME). 35 Only one large noninferiority study in DME patients (RETAIN) used a treatment approach with extended and reduced follow-up intervals and was considered an "extend-and-treat" study. 36 In RETAIN, patients with DME were randomized to intravitreal ranibizumab with the possibility to modify intervals with laser (Group 1; n = 121) or without laser (Group 2; n = 128) and intravitreal ranibizumab PRN (Group 3; n = 123) over a 24-month follow-up. Both approaches with modified intervals were noninferior to PRN based on mean BL, baseline; CNV, choroidal neovascularization; FU, follow-up; IVR, intravitreal ranibizumab; LogMAR, logarithm of the minimum angle of resolution; nAMD, neovascular age-related macular degeneration; PRN, pro re nata; TER, treat-and-extend; VA, visual acuity.
average best-corrected visual acuity change from baseline to Month 1 through Month 12 (+5.9 and +6.1 vs. +6.2 letters; both P , 0.0001). There was an approximately 40% reduction in patient visits in the groups with modified intervals. The design of RETAIN highlights that proactive approaches, such as TER, may be more important to consider in nAMD because it is a more aggressive condition than DME.
Monitoring TER Outcomes Following Anti-VEGF TER Imaging modalities. It is important to use the most accurate methods to monitor long-term follow-up. The TER studies outlined in Table 3 mainly used spectraldomain OCT or time-domain OCT for measuring fluid as the primary method for treatment extension, and some studies used fluorescein angiography (FA) as a secondary method, particularly if interval shortening was being considered. Leakage on FA, even if not shown on OCT, was one criterion for reverting back to more intensive treatment. We assume that all OCT techniques were performed in accordance with established protocols; however, none of the studies correlated the findings if several OCT techniques were used, and they were not Level 1 type studies.
The reliance on OCT to guide dosing intervals may also be confounded by the data showing that there is often low agreement between spectral-domain OCT and time-domain OCT, particularly for advanced features, such as hard exudates, 37 and also for retinal thickness measurements. 38 A number of studies have reported that spectral-domain OCT may be superior to time-domain OCT for detecting subretinal fluid (SRF) 39, 40 and for identifying abnormalities in the absence of fluorescein leakage from choroidal neovascularization. 41 Taken together, these findings indicate that an absence of fluid on spectral-domain OCT or time-domain OCT, resolution of persistent hemorrhage and no new-onset hemorrhage, and no leakage on FA are a benchmark for establishing accurate treatment intervals for TER in nAMD. Fluorescein angiography is also a sensitive technique in detecting leakage associated with ME, making spectral-domain OCT and FA useful for obtaining a comprehensive evaluation in other retinal diseases. 42 The vitreomacular interface, as imaged with OCT, may also have an influence on treatment intervals in nAMD patients using TER. 43 In one study of 64 nAMD patients, the mean visual acuity in the non-vitreomacular adhesion group (n = 49) was 20/66 compared with 20/67 in the vitreomacular adhesion group (n = 15) at Year 1. The mean central retinal thickness values were 264 mm and 308 mm, respectively. The mean total number of injections was 7.6 (non-vitreomacular adhesion) and 8.7 (vitreomacular adhesion) (P = 0.028), and the mean interval between injections was 7.5 weeks versus 6.3 weeks (P = 0.022). Applying more sensitive imaging techniques could result in a more accurate prediction of treatment intervals. Other imaging modalities may be considered as optional; however, they are not required for using a TER approach in most patients.
Baseline characteristics. Several studies have examined the relationship between baseline characteristics and long-term outcomes in an attempt to determine predictors of clinical outcomes and to identify eyes that would benefit most from a TER strategy; this is particularly relevant in today's environment because treatment is often started earlier in patients with better baseline visual acuity. One retrospective review involving 230 eyes with nAMD that were treated with intravitreal bevacizumab using TER found that thinner central macular thickness was independently associated with fewer injections. In the multivariate analysis, a greater number of injections was consistently found to be an independent predictor of better vision at all the time points evaluated (6 months, 1, 2, 3, and 4 years). The mean number of injections per year was 8.8, 7.7, 8.1, and 7.8, respectively. These findings highlight the benefit of TER across all lesion types but show that the best visual outcomes occur in eyes with Type 1 lesions.
Biomarkers. Biomarkers could be a useful adjunct in determining TER strategy in patients who may be nonresponders. 45, 46 In one study, a wide range of proteins was measured using reverse phase microarrays in the preinjection vitreous aspirates from nAMD patients at monthly injection visits before TER. PDGFRb Y751 and VEGFR2 Y951 were significantly increased in the vitreous of patients who responded with worsening visual acuity (i.e., decrease $10 letters) during TER. 45 However, the practical implementation of such assays and techniques in clinical practice may limit the usefulness of their outcomes, except in difficult cases, such as recalcitrant patients or those with a long disease history.
TER Algorithm
Based on the available scientific evidence described, and the experience of the consensus panel, an algorithm on the working definition of TER with anti-VEGF agents in retinal diseases (nAMD, ME/RVO, DME) was devised and is shown in Figure 1 . The consensus panel agreed that monthly injections should continue until the following (maximum response) is observed: 1) complete resolution of SRF and intraretinal fluid (IRF) without new retinal hemorrhage or 2) no further reduction of SRF or IRF on OCT for at least 2 consecutive visits in the absence of new retinal hemorrhage. Some panel members would also include 3) no further flattening of serous or vascularized pigment epithelial detachments and 4) no further improvement in visual acuity, in their definition of maximal response. In general, the consensus panel agreed that angiography is not needed in most patients to determine when maximal response has been reached. Once maximal response is achieved, treatment intervals can be extended if there is either a continued absence (preferred) or stabilization of fluid (i.e., no change in IRF or SRF for at least two consecutive injections) on OCT and no new hemorrhage. As small fluctuations in visual acuity are commonly observed in patients seen frequently for intravitreal anti-VEGF injections, the consensus panel felt that visual changes should be evaluated in the context of the clinical examination and OCT findings if they are to be used in guiding the treatment interval. For example, visual acuity loss without signs of choroidal neovascularization activity should not prompt the need for aggressive treatment change, particularly as visual acuity changes could be linked to other factors.
In some eyes with persistent IRF or SRF, a careful review of the OCT and/or additional imaging with angiography may help identify its source. For example, in nAMD, disruption of the outer retinal architecture over fibrovascular tissue or the presence of Type 3 NV (retinal angiomatous proliferation) may be associated with persistent IRF despite monthly treatment. Fluorescein angiography may be useful for detecting lesion growth that may go unnoticed when imaging eyes frequently with OCT. Indocyanine green angiography may help identify polypoidal choroidal vasculopathy that can show resistance to anti-VEGF therapy. In nAMD, ME/RVO, and DME, OCT may show epiretinal membranes or vitreomacular traction that may be related to persistent IRF.
The consensus panel agreed that treatment can be extended by up to 2 weeks at a time if the disease remains stable. The "standard" maximum extension period was considered to be 12 weeks; however, this may also depend on the nature of the disease being treated, for example, shorter for nAMD compared with DME or ME/RVO, monocular patients, eyes at high risk for hemorrhage (e.g., patients taking anticoagulants or those with very large lesions), and the drug being used.
If a patient shows signs of deterioration resulting from disease activity, then the injection interval should be shortened by 1 week to 2 weeks for a minor change (e.g., small recurrences of fluid or small increases in previously stable fluid on OCT, particularly when these changes are accompanied by small degrees of visual loss [,6 letters], or new small, extrafoveal subretinal hemorrhage [even when not accompanied by any vision loss]). If the deterioration is severe (e.g., large recurrences of fluid or large increases in previously stable fluid on OCT, particularly when these changes are accompanied by large degrees of visual loss [$6 letters], any subfoveal hemorrhage or large extrafoveal macular hemorrhage [even when not accompanied by any vision loss]), then the patient should be reevaluated, and examination of the reasons for deterioration (e.g., FA and/or indocyanine green angiography) may need to be undertaken. In this situation of severe deterioration, reinduction with monthly injection may be considered. Reassessment of treatment interval can be considered once maximal response after a reduced interval is again achieved for two to three consecutive visits. Other longer-term factors to consider following reinjection at maximum interval (and depending on success) include dose change, use of combination therapy, laser, medication change, or treatment suspension.
Further considerations. Although there was some concern regarding the potential development of geographic atrophy, the consensus panel agreed that, in most instances, current evidence favors proactivity with a TER approach rather than risking the negative effects associated with undertreatment. At present, there are insufficient data to determine the association between geographic atrophy and overtreatment with anti-VEGF agents. Studies such as CATT 47-51 might be more safely managed with a PRN regimen to reduce the risk of geographic atrophy progression. A new study in 91 patients (94 eyes) showed that treatment-naive age-related macular degeneration patients with Type 1 NV were significantly (P , 0.001) less likely to develop geographic atrophy after anti-VEGF treatment compared with other subtypes. The majority of patients received ranibizumab (63.8%), bevacizumab (9.6%), ranibizumab plus bevacizumab (5.3%), ranibizumab plus intravitreal aflibercept (18.1%), or all 3 agents (3.2%); the mean follow-up was 28.5 months and the mean number of injections was 17.4. 48 The consensus panel also suggested that a TER approach may reduce the risk of intraocular pressure (IOP) elevation compared with monthly (but not PRN) dosing; prevalence of sustained IOP was significantly higher when the intervals between injections were ,8 weeks compared with $8 weeks (17.6% vs. 6%, P = 0.009). 52 In a 6-month retrospective study of 328 patients (449 eyes) with nAMD treated with intravitreal ranibizumab or bevacizumab, 32 eyes (7.1%) developed sustained IOP (defined as absolute IOP .25 mmHg, increase above baseline .10 mmHg, or IOP of .21 mmHg and increase of .5 mmHg) that was significantly linked to the number of injections (hazard ratio, 1.085; 95% confidence interval, 1.06-1.11). 53 Physicians may also need to consider the differences between transient postinjection IOP spikes related to injection volume and needle gauge and sustained IOP elevation occurring over the course of long-term treatment, and risk factors such as preexisting glaucoma, ocular hypertension, and rapid injection technique. [54] [55] [56] Another study in 22 patients (44 eyes) with nAMD showed no significant difference in retinal nerve fiber layer thickness between eyes treated with intravitreal ranibizumab using TER and the untreated fellow eye. Furthermore, there was no difference in retinal nerve fiber layer thickness in eyes treated with fewer or more than five injections. 57 At present, there are few studies to determine patientcentered preferences for TER, including improvements in compliance with less frequent visits and any show that the frequency of anti-VEGF injections remains lower than that recommended in clinical studies, with high discontinuation rates (71% within 24 months). 58, 59 One 4-year longitudinal study that investigated the pattern of discontinuation in 555 patients (600 eyes) with age-related macular degeneration treated with a variable intravitreal ranibizumab dosing regimen from 2007 to 2011 found that 68% (408 eyes) discontinued: 28% because of lack of response, 11% failure to follow-up, 9% death, and 20% disease inactivity. Treatment was resumed for 18% in this last group, suggesting that eyes with inactivity should still be monitored. 60 It is possible that using a longer interval for treatment follow-up could address some of the issues observed in observational settings. In the long-term study, Mrejen et al 44 reported that the retention rate was 64% over a mean follow-up of 3.6 years in 231 nAMD patients treated with anti-VEGF agents using a TER approach. These findings indicate that a TER may improve retention rates in the long term, but this has yet to be investigated in large-scale observational cohorts. About the issue of tolerance to fluid, some eyes with Type 1 NV managed with TER can have good long-term visual outcomes with anti-VEGF therapy despite some persistent SRF throughout the course of treatment. 15, 61 From a cost perspective, the TER approach could be associated with cost benefits compared with monthly regimens. As an early indication, Gupta et al 16 reported that the mean direct costs (per patient) of the intravitreal ranibizumab TER used in their study were US $16,114.52 (Year 1) and US $13,971.44 (Years 1-2), respectively; this was lower than that observed over a 1-year period in MARINA/ANCHOR (US $28,314.16). However, these cost estimates are now outdated, and any cost analyses would benefit from inclusion of a wider cohort.
It must also be noted that a physician may consider a number of reasons for not choosing TER, including patient choice, preference for minimal number of injections, particularly in bilateral eye disease, severe glaucoma where repeat pressure spikes may be a concern, previous endophthalmitis, or other adverse reactions.
Conclusion
The aim of this consensus article is to consider the best-practice approach to the use of a TER regimen with anti-VEGF agents (intravitreal ranibizumab, bevacizumab, and aflibercept) based on available scientific evidence and clinical experience. There are a number of limitations associated with this nonsystematic review and consensus. First, the published studies of anti-VEGF TER are low-grade, nonregistration studies, which are not Level 1 type evidence. The studies would therefore be subject to issues inherent with the retrospective design of many of them. Other issues include selection bias (including the exclusion of noncompliant patients); the use of different imaging techniques, with no correlation between OCT modalities used; and Type II errors, arising from the lack of monthly regimens for comparison of efficacy and safety outcomes. The consensus also represents the view of clinical experts in the field and is subject to bias and limitations associated with health care systems in different countries. The international, observational AURA (a retrospective non-interventional study to assess the effectiveness of existing Anti-vascular endothelial growth factor treatment Regimens in patients with wet Age-related macular degeneration) study found that patients are undertreated with ranibizumab in real-life settings; this may be because of the difficulty of using monthly regimens in clinical practices. 62 The TER algorithm represents a useful guide that may lead to an improvement in the minimum number of injections being used and may help address some of these issues. The TER is practical and realistic in that it does not overemphasize the need to achieve complete absence of fluid. It must be noted, however, that this is a general guide and may not be applicable to unusual cases in which physician expertise is required.
In summary, TER is considered a suitable approach in a variety of retinal diseases-given that all eyes differ in their need for injections (Table 6) . A generic TER approach could be used in most diseases, based on achievement of a maximum (preferably optimal) response followed by 1-week to 2-week extension intervals that are guided by anatomical measures, with visual changes as a secondary guide for interval extension. The maximum extension period may depend on the anti-VEGF agent used. If disease activity increases, the injection period should be shortened by 2 weeks, with complete reassessment for a major change (such as hemorrhage). There are also a number of well-designed, randomized studies that are ongoing that will help further refine the optimal approach to TER when these data become available.
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